References
- Mannuci PM, Canciani MT, Rota L, Donovan BS. Response of factor VIII/von Willebrand factor to DDAVP in healthy subjects and patients with haemophilia A and von Willebrand disease. Br J Haematol. 1981;47(2):283–93.
- Franchini M. Advances in the diagnosis and management of von Willebrand disease. Hematology. 2006;11(4):219–25.
- Mannucci PM, Vicente V, Alberca I, Sacchi E, Longo G, Harris AS, et al. Intravenous and subcutaneous administration of desmopressin (DDAVP) to hemophiliacs: pharmacokinetics and factor VIII responses. Thromb Haemost. 1987;58:1037–9.
- Nichols WL, Rick ME, Ortel TL, Montgomery RR, Sadler JE, Yawn BP, et al. Clinical and laboratory diagnosis of von Willebrand disease: a synopsis of the 2008 NHLBI/NIH guidelines. Am J Hematol. 2009;84(6):366–70.
- Akin M, Kavakli K. Laboratory diagnosis and management of von Willebrand disease in Turkey: Izmir experience. Semin Thromb Hemost. 2011;37:581–6.
- Michiels JJ, van de Velde A, van Vliet HH, van der Planken M, Schroyens W, Berneman Z. Response of von Willebrand factor parameters to desmopressin in patients with type 1 and type 2 congenital von Willebrand disease: diagnostic and therapeutic implications. Semin Thromb Hemost. 2002;28(2):111–32.
- Mannucci PM, Bettega D, Cattanco M. Patterns of development of tachyphylaxis in patients with haemophilia and von Willebrand disease after repeated doses of desmopressin (DDAVP). Br J Haematol. 1992;82(1):87–93.
- Miesbach W, Krekeler S, Dück O, Llugaliu B, Asmelash G, Schüttrumpf J, et al. Clinical assessment of efficacy and safety of DDAVP. Hamostaseologie. 2010;30:172–5.
- Akin M. Laboratory diagnostic approach of the parents–children relationship in differentiating low-level von Willebrand factor from mild type 1 von Willebrand disease. Blood Coagul Fibrinolysis. 2012;23:351–3.
- Rodeghero F, Castaman G, Mannuci PM. Prospective multicentre study on subcutaneous concentrated desmopressin for home treatment of patients with von Willebrand disease and mild or moderate haemophilia A. Thromb Haemost. 1996;76(5):692–6.
- Akin M, Karapinar YD, Balkan C, Ay Y, Kavakli K. An evaluation of the DDAVP infusion test with PFA-100 and vWF activity assays to distinguish vWD types in children. Clin Appl Thromb Hemost. 2011;17:441–8.
- Sánchez-Luceros A, Meschengieser SS, Woods AI, Chuit R, Turdó K, Blanco A, et al. Biological and clinical response to desmopressin (DDAVP) in a retrospective cohort study of children with low von Willebrand factor levels and bleeding history. Thromb Haemost. 2010;104(5):984–9.
- Revel-Vilk S, Schmugge M, Carcao MD, Blanchette P, Rand ML, Blanchette VS. Desmopressin (DDAVP) responsiveness in children with von Willebrand disease. J Pediatr Hematol Oncol. 2003;25(11):874–9.
- Santoro C, Hsu F, Dimichele DM. Haemostasis prophylaxis using single dose desmopressin acetate and extended use epsilon aminocaproic acid for adenotonsillectomy in patients with type 1 von Willebrand disease. Haemophilia. 2012;18(2):200–4.
- Witmer CM, Elden L, Butler RB, Manno CS, Raffini LJ. Incidence of bleeding complications in pediatric patients with type 1 von Willebrand disease undergoing adenotonsillar procedures. J Pediatr. 2009;155(1):68–72.
- Castaman G, Lethagen S, Federici AB, Tosetto A, Goodeve A, Budde U, et al. Response to desmopressin is influenced by the genotype and phenotype in type 1 von Willebrand disease (VWD): results from the European Study MCMDM-1VWD. Blood. 2008;111(7):3531–9.
- Federici AB, Mazurier C, Berntorp E, Lee CA, Scharrer I, Goudemand J, et al. Biologic response to desmopressin in patients with severe type 1 and type 2 von Willebrand disease: results of a multicenter European study. Blood. 2004;103(6):2032–8.
- Favaloro EJ, Kershaw G, Bukuya M, Hertzberg M, Koutts J. Laboratory diagnosis of Von Willebrand Disorder (VWD) and monitoring of DDAVP therapy: efficacy of the PFA-100 and VWF:CBA as combined diagnostic strategies. Haemophilia. 2001;7(2):180–9.
- Cattaneo M, Federici AB, Lecchi A, Agati B, Lombardi R, Stabile F, et al. Evaluation of the PFA-100 system in the diagnosis and therapeutic monitoring of patients with Von Willebrand disease. Thromb Haemost. 1999;82(1):35–9.
- Favaloro EJ. Laboratory monitoring of therapy in von Willebrand disease: efficacy of the PFA-100 and von Willebrand factor:collagen-binding activity as coupled strategies. Semin Thromb Hemost. 2006;32(6):566–76.
- Favaloro EJ. Clinical utility of the PFA-100. Semin Thromb Hemost. 2008;34(8):709–33.
- Akin M, Polat Y. Platelet function analyser (PFA)-100(®) closure time in the evaluation of non-steroidal anti-inflammatory drug-induced platelet dysfunction in children with bleeding symptoms. Blood Transfus. 2012;10:545–6.